- $25.77bn
- $25.06bn
- $4.66bn
Annual cashflow statement for DexCom, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 155 | 341 | 542 | 576 | 836 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 323 | 167 | 72.8 | 131 | 67 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -132 | 26.7 | 3.2 | 109 | 103 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 443 | 670 | 749 | 990 | 1,441 |
| Capital Expenditures | -389 | -365 | -237 | -359 | -364 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 173 | -157 | -271 | 151 | 900 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -216 | -522 | -507 | -208 | 536 |
| Financing Cash Flow Items | -9.9 | -17.3 | -99.8 | -13 | -7 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 10.4 | -553 | -319 | -735 | -1,686 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 235 | -410 | -75.8 | 39.8 | 312 |